Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts $10.13 -0.03 (-0.31%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Keros Therapeutics Earnings Summary Keros Therapeutics announced Q1 2026 earnings on May 14, 2026, reporting an EPS of -$1.21, which missed the consensus estimate of -$1.02 by $0.19. Quarterly revenue was reported to be $0.37 million, below analyst estimates of $1.93 million. With a trailing EPS of -$3.01, Keros Therapeutics' earnings are expected to decrease next year, from ($4.93) to ($5.15) per share. Upcoming Q2 Earnings DateAug. 5Before Market OpensEstimatedConsensus EPS (May. 14) -$1.02 Actual EPS (May. 14) -$1.21 Missed By -$0.19 Actual Revenue (May. 14) $0.37MQ1 2026 Earnings ResourcesQ1 2026 Earnings Report Press Release (8-K) Quarterly Report (10-Q)SEC FilingKROS Upcoming EarningsKeros Therapeutics' next earnings date is estimated for Wednesday, August 5, 2026, based on past reporting schedules. Powered by Get Keros Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20262-$0.89-$0.65-$0.77Q2 20262-$1.27-$0.73-$1.00Q3 20262-$1.31-$0.73-$1.02Q4 20262-$1.33-$0.73-$1.03 Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/5/2026(Estimated)--------5/14/2026Q1 2026-$1.0229-$1.21 -$0.1871-$1.21$1.93M$0.37M3/4/2026Q4 2025-$0.49-$0.86 -$0.37-$0.86$3.66M$0.39M11/5/2025Q3 2025-$1.11-$0.18+$0.93-$0.18$4.22M$14.26M8/6/2025Q2 2025-$1.14-$0.76+$0.38-$0.76$3.83M$0.02M5/6/2025Q1 2025-$0.01$3.62+$3.63$3.62$84.62M$211.25M2/26/2025Q4 2024-$1.36-$1.14+$0.22-$1.14$37.32M$3.04M11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M Data powered by Fiscal.ai. Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics' earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 5th, 2026 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) missed the analysts' consensus estimate of ($1.02) by $0.19 with a reported earnings per share (EPS) of ($1.21). Learn more on analysts' earnings estimate vs. KROS's actual earnings. How can I view Keros Therapeutics' earnings report? Keros Therapeutics' earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $244.06 million. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of $87.01 million. KROS has generated -$3.01 earnings per share over the last four quarters. What is Keros Therapeutics' EPS forecast for next year? Keros Therapeutics' earnings are expected to decrease from ($4.93) per share to ($5.15) per share in the next year. More Earnings Resources from MarketBeat Related Companies ANNX Earnings SPRY Earnings CGEM Earnings LBRX Earnings MGTX Earnings DSGN Earnings JANX Earnings TBPH Earnings ABUS Earnings DRUG Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?Why Applied Optoelectronics Stock May Be Near a Turning PointIs Everspin Technologies the Next AI Edge Breakout?Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavault Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different Stories This page (NASDAQ:KROS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
